[Clinico-hematological effectiveness in losartan for treating hypertensive patients].
Effects were studied of a 6-week lozartan monotherapy, 50 mg daily, on the systemic hemodynamics, morphofunctional characteristics of the left ventricle (LV), lipid, carbohydrate, purin metabolisms, and some parameters characterizing renal function in patients with mild and moderately severe hypertensive disease (HD). A 24-h monitoring of arterial pressure (AP) was conducted in the above patients. Lozartan proved to be effective hypertensive medication in mild and moderately severe HD, capable of decreasing significantly total peripheral resistance with no reflex tachycardia developing. The drug has been shown to reduce nightly "pressure load" and AP in the small hours as well, and to improve the contractile and pumping function of the myocardium making for regression of LV hypertrophy, with no side effects noted.
Mysnychenko
O V
OV
D000328:Adult; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D019808:Losartan / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged
D000959:Antihypertensive Agents; D019808:Losartan